Patents Assigned to Glaxo Group Limited
  • Muscarinic acetylcholine receptor antagonists
    Patent number: 9045469
    Abstract: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: June 2, 2015
    Assignee: Glaxo Group Limited
    Inventors: Dramane Ibrahim Laine, Michael R. Palovich, Brent W. McCleland, Christopher E. Neipp, Sonia M. Thomas
  • Anti-serum albumin binding variants
    Patent number: 9040668
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: May 26, 2015
    Assignee: Glaxo Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
  • Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists
    Patent number: 9028817
    Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: May 12, 2015
    Assignee: Glaxo Group Limited
    Inventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
  • Inhibitors of SP140 and their use in therapy
    Patent number: 9018184
    Abstract: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of bromodomain-containing protein: SP140.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: April 28, 2015
    Assignee: Glaxo Group Limited
    Inventors: Kevin Lee, David Francis Tough
  • Silica abrasive-free dentifrice composition
    Patent number: 9011824
    Abstract: A dentifrice composition providing superior shine and polish, low RDA and effective whitening comprising a calcined aluminum oxide polishing agent, a water soluble condensed phosphate such as an alkali metal phosphate salt and an orally acceptable carrier or excipient is described. The composition is free of a silica abrasive.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: April 21, 2015
    Assignee: Glaxo Group Limited
    Inventors: Frank Lippert, Robert Anthony Lucas
  • 3-amino-pyrazole derivatives useful against tuberculosis
    Patent number: 9000181
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3 alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: April 7, 2015
    Assignee: Glaxo Group Limited
    Inventors: Raquel Fernandez Menendez, Silvia Gonzalez Del Valle
  • AGGREGATE NANOPARTICULATE MEDICAMENT FORMULATIONS, MANUFACTURE AND USE THEREOF
    Publication number: 20150093440
    Abstract: A method of making aggregate particles suitable for a powder aerosol composition that includes forming a dispersion of nanoparticulate drug and/or excipient in a non-aqueous liquid, and spray-drying the dispersion to generate aggregate particles having a mass median aerodynamic diameter of less than or equal to about 100 microns, and particles generated by such method, and compositions of said particles.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 2, 2015
    Applicant: GLAXO GROUP LIMITED
    Inventors: Michiel M. Van Oort, John N. Hong
  • Compounds
    Patent number: 8993560
    Abstract: A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: March 31, 2015
    Assignee: Glaxo Group Limited
    Inventors: Francis Louis Atkinson, Michael David Barker, John Liddle, David Matthew Wilson
  • 6-(1-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof
    Patent number: 8993576
    Abstract: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr, Robert David Willacy
  • 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors
    Patent number: 8975400
    Abstract: Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA2,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: March 10, 2015
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Kai Long, Yingxia Sang, Xiaobo Su
  • Treatment of stroke comprising anti-MAG antibodies
    Patent number: 8974782
    Abstract: The present invention relates to a dosing regimen for use in the treatment of stroke. More particularly, the invention relates to the administration of two doses of anti-MAG antibodies for the treatment of ischemic and/or haemorrhagic stroke.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: March 10, 2015
    Assignee: Glaxo Group Limited
    Inventors: Bams Abila, Lori Ann Enney, Seth Paul Finklestein, Volker Germaschewski, Robert Ian Grundy, Elaine Alison Irving, Monica Simeoni
  • NOVEL COMPOUNDS
    Publication number: 20150065507
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Application
    Filed: April 25, 2013
    Publication date: March 5, 2015
    Applicant: Glaxo Group Limited
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • CD127 binding proteins
    Patent number: 8940303
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: January 27, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alex H. Taylor, Thomas Matthew Webb, Yu Xue
  • Substituted diketopiperazines and their use as oxytocin antagonists
    Patent number: 8937179
    Abstract: Compounds of formula (1) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 20, 2015
    Assignee: Glaxo Group Limited
    Inventor: John Liddle
  • Container
    Patent number: D721586
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: January 27, 2015
    Assignee: Glaxo Group Limited
    Inventors: Tim Sharpe, Jonathan Stewart, Stuart Cole
  • Toothbrush
    Patent number: D723808
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: March 10, 2015
    Assignee: Glaxo Group Limited
    Inventors: Richard Brian Clough, Martin Crofton, Peter Kay, Simon Ritchie
  • Container
    Patent number: D724443
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: March 17, 2015
    Assignee: Glaxo Group Limited
    Inventors: Tim Sharpe, Jonathan Stewart, Stuart Cole
  • Container
    Patent number: D728360
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 5, 2015
    Assignee: Glaxo Group Limited
    Inventor: Andrew Michael Kelly
  • Container
    Patent number: D728361
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 5, 2015
    Assignee: Glaxo Group Limited
    Inventors: Stuart John Farley, Andrew Michael Kelly
  • Container
    Patent number: D728362
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 5, 2015
    Assignee: Glaxo Group Limited
    Inventor: Andrew Michael Kelly